Volume | 3,384,633 |
|
|||||
News | - | ||||||
Day High | 4.0899 | Low High |
|||||
Day Low | 2.57 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Genprex Inc | GNPX | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
2.77 | 2.57 | 4.0899 | 3.11 | 2.42 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
19,459 | 3,384,633 | $ 3.13 | $ 10,580,557 | - | 2.09 - 42.40 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:59:56 | 25 | $ 3.60 | USD |
Genprex Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
4.67M | 1.49M | - | 0 | -30.86M | -20.77 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Genprex News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical GNPX Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 2.22 | 4.0899 | 2.10 | 2.29 | 28,588 | 1.43 | 64.41% |
1 Month | 2.39 | 4.0899 | 2.10 | 2.44 | 40,005 | 1.26 | 52.72% |
3 Months | 4.25 | 5.048 | 2.09 | 3.11 | 47,427 | -0.60 | -14.12% |
6 Months | 9.628 | 14.40 | 2.09 | 8.41 | 266,081 | -5.98 | -62.09% |
1 Year | 32.128 | 42.40 | 2.09 | 20.12 | 393,012 | -28.48 | -88.64% |
3 Years | 149.60 | 162.80 | 2.09 | 96.82 | 843,050 | -145.95 | -97.56% |
5 Years | 62.80 | 308.80 | 2.09 | 117.63 | 1,275,611 | -59.15 | -94.19% |
Genprex Description
Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex's oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The resultant product is administered intravenously, where it is taken up by tumor cells that then express tumor suppressor proteins that were deficient in the tumor. |